Income statement, balance sheet and cash flow statement for the last 5 fiscal years, taken from the XBRL data Abivax S.A. files with the SEC in its annual reports.
In EUR millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2021
FY2023
FY2023
FY2024
FY2025
Research and development
47.8
48.3
103
147
178
Operating income
-41.4
-64.8
-127
-173
-246
Interest expense
3.56
7.02
27.9
17
112
Interest income
2.51
11.1
7.51
13.7
27.5
Pre-tax income
-42.5
-60.7
-148
-176
-330
Income tax
0
0
0
0
5.85
Net income
-42.5
-60.7
-148
-176
-336
EPS, basic
-2.75
-3.18
-3.43
-2.80
-4.83
EPS, diluted
-2.75
-3.18
-3.43
-2.80
-4.83
Balance sheet
FY2021
FY2023
FY2023
FY2024
FY2025
Cash and equivalents
60.7
27
252
144
517
Total current assets
75.5
36.2
286
171
551
Goodwill
32
18.4
18.4
18.4
18.4
Intangible assets
0.09
6.61
6.6
6.61
6.61
Total assets
109
75.5
327
205
584
Accounts payable
18.6
15.5
47.2
43.8
37.6
Total current liabilities
32.3
51.5
90.7
94
63
Total liabilities
83.3
68.4
131
165
129
Paid-in capital
108
150
478
479
1,191
Total equity
25.9
7.19
196
40.6
455
Total liabilities and equity
109
75.5
327
205
584
Cash flow statement
FY2021
FY2023
FY2023
FY2024
FY2025
Net income
-42.5
-60.7
-148
-176
-336
Cash from operations
-45
-53.9
-97.1
-154
-161
Capital expenditures
-0.05
-0.29
-0.27
-0.64
-0.14
Cash from investing
-6.23
-12
-8.1
15.8
-8.19
Stock issued
69.7
46.2
353
0
648
Cash from financing
82.7
32.2
335
28.2
547
Exchange rate effect
0
0
-5.07
2.38
-10.3
Net change in cash
31.4
-33.8
225
-108
372
Free cash flow
-45.1
-54.2
-97.4
-155
-161
Income taxes paid
0
0
0
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. No valuation: the share price is quoted in a different currency than the statements.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
-85.1%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Total assets growth, 1y
184.7%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
97.8%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
8.75x
Current assets / current liabilities.
Quick ratio
8.20x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
8.20x
(Cash + short-term investments) / current liabilities.
Liabilities / assets
22.1%
Total liabilities / total assets.
Interest coverage
-2.20x
Operating income / interest expense.
Working capital
€488.2M
Current assets - current liabilities.
Goodwill and intangibles / assets
4.3%
(Goodwill + intangible assets) / total assets.
Per share
Metric
Value
How it is calculated
EPS, diluted
-€4.83
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-€4.83
Net income per basic share, as reported (split-adjusted).
Was Abivax S.A. profitable in fiscal 2025?
No. It reported a net loss of €336.1M.
How much free cash flow did Abivax S.A. generate in fiscal 2025?
Cash from operations of €161.1M minus capital expenditures of €142.0K left free cash flow of -€161.3M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.